Get Our FREE Newsletter

Sign Up

Down 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

Spread the love

Corvus Pharmaceuticals (CRVS) has been beaten down lately with too much selling pressure. While the stock has lost 15.8% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to rep

This post was originally published on this site